NewsRoom Articles - Page 19 of 44

WednesdayJul 26, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Set to be Used in Multi-Billion Dollar Markets; On Track to have 2023 as Best Year Yet

Lexaria’s patented DehydraTECH(TM) technology enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats This unique approach to drug delivery has earned Lexaria a total of 35 patents, with many patents pending worldwide The company continues active discussions with multi-billion dollar companies for the potential use of DehydraTECH in their commercial pursuits Lexaria is also actively seeking commercial partners during 2023 and 2024 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is out on an ambitious move to address conditions with high unmet needs. This focus has allowed them…

MondayJul 24, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Collaboration With Trucker Tools Boosts Strength of Shipping Networks in United States

Freight Technologies (aka Fr8Tech) is a growing commercial freight transportation technology developer whose flagship Fr8App platform helps shippers and carriers easily match loads and destinations in the USMCA Trucker Tools is a trip planning, shipment visibility, predictive freight matching and automated booking solutions company that has developed its flagship Smart Capacity(R) platform Fr8Tech recently announced integration of Trucker Tools’ network, boosting the pool of truck drivers able to use Fr8App by more than 315,000 carriers The collaboration is expected to increase the offers on loads by 75 percent and grow the carrier network for loads originating from and destined to…

MondayJul 24, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Publishes Eighth Peer-Reviewed Article in International Journal of Molecular Science

The article covers the concentration of cannabidiol in hypertensive women and men using the company’s patented DehydraTECH(TM)-processed CBD The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1% The article supports Lexaria’s efforts as it pursues IND status from the FDA for DehydraTECH-CBD as a potential treatment for hypertension Company is planning to begin preparations for a clinical trial that could start as early as the fourth quarter Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research…

FridayJul 21, 2023 9:00 am

National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

National awareness of glioblastoma tumors (“GBM”) sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond three years U.S.-based drug developer CNS Pharmaceuticals is in the midst of a global potentially pivotal clinical trial for its lead pharmaceutical candidate, Berubicin, which it aims to show improves on standard of care chemotherapy agent Lomustine’s approach to treating GBM Berubicin is a novel anthracycline that is practically unique in its ability to cross the blood-brain barrier to directly target…

ThursdayJul 20, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Building a Robust and Growing International Patent Portfolio for DehydraTECH(TM) in Support of Commercial Opportunities

Lexaria is a global innovator in drug delivery platforms with an expanding portfolio of patents that currently stands at 34 granted patents and many patents pending worldwide These patents pertain to the company’s method of improving bioavailability and taste as well as the use of DehydraTECH(TM) as a delivery platform for a wide variety of active pharmaceutical ingredients (“APIs”) The company has, since June 2015, simultaneously filed the US utility patent application and an international patent application under the Patent Cooperation Treaty (“PCT”) procedure, both through the USPTO The PCT procedure has made the process of initiating international patent applications…

TuesdayJul 18, 2023 9:45 am

Cepton, Inc. (NASDAQ: CPTN) Accelerates Intelligent Lidar Solutions Critical to Vehicle Safety and Road Management

Cepton advances lidar technology that integrates into traffic systems, intersections, and ADAS-powered vehicles to improve passenger and pedestrian safety Through partnerships with leading global OEMs, CPTN enables ADAS mass-market commercialization with ultra-compact, high-performance, and cost-effective lidar solutions CPTN’s Helius(R) Smart Lidar System was recently deployed in government-funded pedestrian safety projects in Texas and Utah Other applications of CPTN's lidar technology include airport terminal monitoring, security systems, crowd analytics, railway obstacle detection, e-tolling, and traffic management Lidar - a combination of the words “light detection and ranging” – is a sensing technology that sends out laser pulses and measures the time…

FridayJul 14, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Increases Bioavailability in Lipophilic Drugs for Potential Hypertension, Epilepsy Treatments

The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11% Drug developers are shifting focus to the development of lipophilic drug compounds, which increases bioavailability DehydraTECH-enabled drugs improve the speed of onset, increase bioavailability, increases brain absorption, and reduces drug administration costs Lexaria’s DehydraTECH has 34 patents granted worldwide and many more pending across several categories of fat-soluble active molecules and drugs The company operates through four separate subsidiaries to explore the potential and options for the use of DehydraTECH in respective industries Bioavailability is the ability of…

TuesdayJul 11, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update

Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six additional patents awarded across Australia, Japan, the U.S., and Canada so far in 2023 The company also noted its $2 million capital raise back in May, a strong indicator of shareholders’ confidence in the brand, and its efforts to grow its operations Lexaria looks to build on the momentum gathered so far, and its management is…

MondayJul 10, 2023 10:30 am

D-Wave Quantum Inc. (NYSE: QBTS) Technology Ready to Answer Call of Proposed Legislation for Near-Term Quantum Applications to Solve Optimization Problems

Legislation presented to Congress calls for the United States government to develop and adopt near-term quantum computing – some within 24 months or less for developing and deploying demos, proofs of concepts, and pilots Global government spending on quantum application development is expected to reach $36 billion during 2023 D-Wave offers quantum solutions to help government and public sector develop applications that can solve important optimization problems Recent legislation presented to Congress calls for the United States government to develop and adopt near-term quantum computing applications to solve complex public sector optimization problems, which could include electrical grid resilience, optimization…

MondayJul 10, 2023 9:00 am

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year The Safety Review Committee approved the advancement of the Acclaim 1 clinical trial to the Phase 2 expansion portion of the trial Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000